Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma

NCT01711593 | Completed Phase 1 DMC

• 2 other identifiers: 2012P00010761U19AI095261
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

Despite advances in medications, allergic diseases, including allergic asthma continue to rise in prevalence. For this reason, there is a need for a better understanding of the mechanisms of allergic diseases and novel insights into modulating allergic inflammation. The investigators hypothesize that much remains to be learned about the behavior of T effector and T regulatory cells in allergic disease. Furthermore, the investigators hypothesize that novel mechanisms of allergic tolerance may exist, and elucidation of these mechanisms may provide insights into novel therapeutic strategies to control allergic diseases. The investigators will investigate the capacity for T cell tolerance induction in allergic subjects by a novel type of immune tolerizing dendritic cell (it-DC). The investigators will assess whether in vitro generated it-DCs have the capacity to induce antigen-specific T regulatory cells and suppress allergen-specific T effector cell function in vitro. Standardized Cat Allergen extract and Dust Mite Allergens will be used to generate changes in the airways that occur during exposure to allergen. For this investigation, the route of administration will be topical application of the titrated allergen to a bronchoscopically isolated subsegment of one lobe of one lung. The dose of biologic will be determined from prior skin-prick testing.

Conditions

Asthma; Allergies

Keywords

Asthma; Allergic; Inflammation; Airway; Challenge; Chemokines; Tolerization

Outcome Measures

Primary Outcomes (1)

• Effect of it-DC on the phenotype, function, proliferation and survival of allergen-specific effector T cells.

  We will generate induced tolerogenic dendritic cells (it-DCs) in vitro from peripheral blood monocytes and dendritic cells isolated from each allergic asthmatic subject and assess their capacity to (a) attenuate effector CD4+ T cell (Teff) responses and/or (b) induce T regulatory (Treg) cells from Teff cells as well as CD4+ naïve and memory T cells. Attenuation of T cell responses (a) will be assessed by proliferation assays and cytokine production. Moreover, in order to evaluate the functionality of the it-DC induced Tregs (b), co-culture suppression assays using cat or house dust-mite allergen-specific Teff cells isolated from BAL following segmental allergen challenge (SAC) as responder cells, will be examined. The percent suppression of responding Teff cells will be assessed by examining Teff cell proliferation and survival/apoptosis, and by cytokine production. (Note: SAC samples from healthy controls are not involved in the primary analysis.)

  24 hours

Secondary Outcomes (3)

• Percent distribution of peripheral blood DC subsets

  4 weeks

• Percent suppression of naïve T cells (Tn) and memory T cells (Tmem) proliferation by it-DC-induced Tregs from each subject.

  4 weeks

• Differences in proliferation by allergen-specific Teff cells from BAL and blood.

  4 weeks

Study Arms (1)

Allergic Asthmatic, Non-allergic non-asthmatics(HC)

EXPERIMENTAL

Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.

Biological: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage; Procedure: Phlebotomy

Interventions

Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage BIOLOGICAL

On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.

Also known as: One of 3 Standardized allergen extracts will be used:, 1)Cat hair, 2)Dust Mite Dermatophagoides farinae, 3)Dust Mite Dermatophagoides pteronyssinus, Phenolized saline diluent will also be used in this study., All will be purchased from Greer Laboratories Lenoir,NC.

Allergic Asthmatic, Non-allergic non-asthmatics(HC)

Phlebotomy PROCEDURE

200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.

Also known as: Blood Draw

Allergic Asthmatic, Non-allergic non-asthmatics(HC)

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects with Allergic Asthma (AA subjects):
• All subjects will have a baseline FEV1 no less than 75 % of the predicted value after bronchodilator administration.
• All subjects will have both a clinical history of allergic symptoms to cat or dust mite allergen and a positive allergen prick test (3 mm diameter greater than diluent control)
• Life-long absence of cigarette smoking (lifetime total of \< 5 pack-years and none in 5 years).
• Willing and able to give informed consent.
• Expressed the desire to participate in an interview with the principal investigator.
• Age between 18 and 50 years.
• A methacholine PC20 \< 16 mg/ml.
• Asthma of severity defined as: requiring no more than step 3 therapy (NHLBI Guidelines, 2007), well-controlled and having a validated asthma control test (ACT) score of \> 19 for one month prior to the screening visit, and able to tolerate a 2 week stoppage of inhaled corticosteroids prior to Visit 2.
• Healthy Control Subjects (HC subjects):
• Normal control subjects will be individuals who are in good overall health, age and sex matched to the asthmatic group, age 18 - 50 and nonallergic, i.e. entirely negative on the panel of prick skin tests with no history of allergic rhinitis or asthma, no history of allergic symptoms caused by cats or dust mite allergen exposure, life-long nonsmokers of cigarettes (defined as a lifetime total of less than 5 pack-years and none in 5 years), normal spirometry (i.e. FEV1 and FVC of at least 90% of predicted) and with a methacholine PC20 of \> 16 mg/ml.

You may not qualify if:

• Subjects with Allergic Asthma (AA subjects):
• Women of childbearing potential who are pregnant (based on urine beta-HCG testing), are sexually active and not using contraception, are seeking to become pregnant, or who are nursing.
• The presence of spontaneous asthmatic episode or clinical evidence of upper respiratory tract infection within the previous 6 weeks.
• Participation in a research study involving a drug or biologic during the 30 days prior to the study.
• Intolerance to albuterol, atropine, lidocaine, fentanyl, or midazolam.
• Antihistamines within 7 days of the screening visit.
• Presence of diabetes mellitus, congestive heart failure, ventricular arrhythmias, history of a cerebrovascular accident, renal failure, history of anaphylaxis, or cirrhosis.
• Use of systemic steroids, increased use of inhaled steroids, beta blockers and MAO inhibitors or a visit for an asthma exacerbation within 1 month of the screening visit.
• Antibiotic use for respiratory disease within 1 month of the characterization visit or a respiratory tract infection within 6 weeks of the bronchoscopy visits.
• A history of asthma-related respiratory failure requiring intubation.
• Quantitative skin-prick test positive reaction down to an allergen concentration of 0.056 BAU or AU/ml.
• Subjects with a high possibility of poor compliance with the study.
• Have a history of cigarette smoking within the past 5 years or \> 5 pack years total.
• Having second-hand cigarette smoke exposure or indoor furry pets except in the case of dog, if the subject is not allergic to the dog and the subject has a negative skin test to dog.
• Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection.

Sponsors & Collaborators

• Andrew D. Luster, M.D.,Ph.D.: lead
• National Institute of Allergy and Infectious Diseases (NIAID): collaborator

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Asthma; Hypersensitivity; Inflammation

Interventions

Bronchoscopy; Bronchoalveolar Lavage; Phlebotomy; Blood Specimen Collection

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, Respiratory System; Diagnostic Techniques and Procedures; Diagnosis; Endoscopy; Diagnostic Techniques, Surgical; Minimally Invasive Surgical Procedures; Surgical Procedures, Operative; Pulmonary Surgical Procedures; Thoracic Surgical Procedures; Therapeutic Irrigation; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Punctures; Therapeutics

Study Officials

• Andrew D Luster, M.D., Ph.D.

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief, Division of Rheumatology, Allergy, and Immunology

Study Record Dates

• First Submitted: June 28, 2012
• First Posted: October 22, 2012
• Study Start: January 1, 2013
• Primary Completion: September 1, 2016
• Study Completion: September 1, 2016
• Last Updated: September 15, 2017

Record last verified: 2017-09

Locations

US (1)